Laboratory and physiological measurements among patients with vivax and falciparum malaria and healthy controls.

Investigations are performed on enrolment, unless otherwise stated. Numbers are median (IQR) unless otherwise stated. Where a result is below the lower limit of detection (LLD), half the LLD is substituted.
For intergroup comparison between controls, non-severe P. vivax and severe P. vivax; and between controls, non-severe P. falciparum and severe P. falciparum; P values were <0.05 (by Kruskal-Wallis or anova) for all variables tested. All significant differences in laboratory measurements between patients with severe and non-severe vivax malaria remain significant after excluding a severe malaria patient with concurrent pneumococcal bacteremia.
†measured in 50 healthy controls and all patients with malaria
* measured in 30 healthy controls, all patients with severe malaria, 29 patients with non-severe P. vivax and 35 patients with non-severe P. falciparum
∧measured in 30 healthy controls, all patients with severe malaria, all patients with P. falciparum, and 46 patients with non-severe P. vivax
#measured in 67 controls, 8 patients with severe P. vivax, 33 patients with non-severe P. vivax, 19 patients with severe P. falciparum, and 72 patients with non-severe P. falciparum
Laboratory and physiological measurements among patients with vivax and falciparum malaria and healthy controls.